← United States · Coverage record
US · SEC FORM 4
Entrada Therapeutics, Inc.
TRDA · Nasdaq · CIK 0001689375 · Healthcare · Biotechnology
INSIDER SIGNAL
No active buy signal
1 qualifying P purchase group
in the current 180-day scoring window
41 Form 4 transaction lines observed in the same window
35 sales · 5 option, withholding, award, gift or other lines
Last qualifying purchase2026-05-20 · Zeiher Bernhardt G · $29.3K
WHY NO ACTIVE SIGNAL?
Purchase activityPresent
Recent buying1 qualifying line group(s)
Recent salesHigh
Buy signal statusInactive
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Insider activity timeline
Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.
AprMayJunJulAugSepOct
MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 GP LLC; MPM BioVentures 2018 LLCTenPercentOwner
▼▼▼▼▼▼▼▼▼▼▼▼
EVNIN LUKE; Foley Todd; GADICKE ANSBERT; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM Asset Management Investors BV2014 LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2014 (B), L.P.; MPM BioVentures 2014 GP LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014, L.P.TenPercentOwner
▼▼▼▼▼▼▼▼▼▼▼▼
PARMAR KUSHDirector
▼▼▼▼▼
5AM Opportunities I (GP), LLC; 5AM Opportunities I, L.P.; 5AM Partners V, LLC; 5AM Ventures V, L.P.; ROCKLAGE SCOTT M; Schwab Andrew J.TenPercentOwner
▼▼▼▼
WENTWORTH KORY JAMESChief Financial Officer
○
Sethuraman NatarajanPresident, Research & Develop.
○
● Purchase▼ Sale○ Other
Showing the six most active owners; 3 additional owner(s) remain in Form 4 evidence.
Purchase breadth & concentration
QUALIFYING BUYERS1
PURCHASE CONCENTRATION100%Largest buyer: Zeiher Bernhardt G · $29.3K
CLUSTER BUYING · 15D1 insiderPeak activity: 2026-05-20–2026-05-20
Roles in the peak window: Director. Concentration uses priced qualifying P lines only and does not change the saved score.
SIGNAL HISTORY
No recorded active-signal snapshot
Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2026-05-20 · Zeiher Bernhardt G.
Recent Form 4 activity
17Purchases
44Sales
17Other Form 4 lines
32SEC filings · 365 days
BUYING1 qualifying P line(s) · 180 days
SELLING35 sale line(s) · context only
OTHER5 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.
Short interest
Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.
- Shares short
- 2,989,455
- Previous report
- 2,744,145
- Avg daily volume
- 303,169
- Days to cover
- 9.9
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-05-20 | Zeiher Bernhardt G | Purchase (P) | Common Stock | 5,000 | USD 5.86 | USD 29,300 | SEC filing ↗ |
| 2025-11-20 | BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC | Purchase (P) | Common Stock | 28,867 | USD 9.07 | USD 261,824 | SEC filing ↗ |
| 2025-11-12 | BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC | Purchase (P) | Common Stock | 100,736 | USD 7.76 | USD 781,447 | SEC filing ↗ |
| 2025-11-11 | BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC | Purchase (P) | Common Stock | 46,434 | USD 7.50 | USD 348,198 | SEC filing ↗ |
| 2025-11-10 | BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC | Purchase (P) | Common Stock | 30,874 | USD 7.21 | USD 222,634 | SEC filing ↗ |
| 2024-05-14 | KIM PETER S | Purchase (P) | Common Stock | 25,000 | USD 14.59 | USD 364,750 | SEC filing ↗ |
| 2024-05-14 | KIM PETER S | Purchase (P) | Common Stock | 25,000 | USD 14.59 | USD 364,750 | SEC filing ↗ |
| 2024-05-13 | KIM PETER S | Purchase (P) | Common Stock | 25,000 | USD 14.68 | USD 367,000 | SEC filing ↗ |
| 2024-05-09 | KIM PETER S | Purchase (P) | Common Stock | 2,200 | USD 14.25 | USD 31,350 | SEC filing ↗ |
| 2024-05-08 | KIM PETER S | Purchase (P) | Common Stock | 2,276 | USD 14.04 | USD 31,955 | SEC filing ↗ |
| 2024-04-08 | KIM PETER S | Purchase (P) | Common Stock | 2,600 | USD 13.57 | USD 35,282 | SEC filing ↗ |
| 2024-03-28 | KIM PETER S | Purchase (P) | Common Stock | 1,512 | USD 13.75 | USD 20,790 | SEC filing ↗ |
| 2024-03-26 | KIM PETER S | Purchase (P) | Common Stock | 2,750 | USD 13.64 | USD 37,510 | SEC filing ↗ |
| 2024-03-25 | KIM PETER S | Purchase (P) | Common Stock | 3,180 | USD 13.36 | USD 42,485 | SEC filing ↗ |
| 2024-03-22 | KIM PETER S | Purchase (P) | Common Stock | 3,118 | USD 13.76 | USD 42,904 | SEC filing ↗ |
Form 4 evidence
78 transaction lines in the latest 365-day window; 438 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-09-09 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 GP LLC; MPM BioVentures 2018 LLC | Sale (S) | Common Stock | 28,837 | USD 7.13 | USD 205,608 | SEC filing ↗ |
| 2026-09-09 | EVNIN LUKE; Foley Todd; GADICKE ANSBERT; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM Asset Management Investors BV2014 LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2014 (B), L.P.; MPM BioVentures 2014 GP LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014, L.P. | Sale (S) | Common Stock | 28,837 | USD 7.13 | USD 205,608 | SEC filing ↗ |
| 2026-09-08 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 GP LLC; MPM BioVentures 2018 LLC | Sale (S) | Common Stock | 192,500 | USD 7.41 | USD 1,426,425 | SEC filing ↗ |
Show recent Form 4 evidence (30 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-09-09 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 GP LLC; MPM BioVentures 2018 LLC | Sale (S) | Common Stock | 28,837 | USD 7.13 | USD 205,608 | SEC filing ↗ |
| 2026-09-09 | EVNIN LUKE; Foley Todd; GADICKE ANSBERT; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM Asset Management Investors BV2014 LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2014 (B), L.P.; MPM BioVentures 2014 GP LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014, L.P. | Sale (S) | Common Stock | 28,837 | USD 7.13 | USD 205,608 | SEC filing ↗ |
| 2026-09-08 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 GP LLC; MPM BioVentures 2018 LLC | Sale (S) | Common Stock | 192,500 | USD 7.41 | USD 1,426,425 | SEC filing ↗ |
| 2026-09-08 | EVNIN LUKE; Foley Todd; GADICKE ANSBERT; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM Asset Management Investors BV2014 LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2014 (B), L.P.; MPM BioVentures 2014 GP LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014, L.P. | Sale (S) | Common Stock | 192,500 | USD 7.41 | USD 1,426,425 | SEC filing ↗ |
| 2026-09-04 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 GP LLC; MPM BioVentures 2018 LLC | Sale (S) | Common Stock | 38,500 | USD 7.11 | USD 273,735 | SEC filing ↗ |
| 2026-09-04 | EVNIN LUKE; Foley Todd; GADICKE ANSBERT; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM Asset Management Investors BV2014 LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2014 (B), L.P.; MPM BioVentures 2014 GP LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014, L.P. | Sale (S) | Common Stock | 38,500 | USD 7.11 | USD 273,735 | SEC filing ↗ |
| 2026-09-03 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 GP LLC; MPM BioVentures 2018 LLC | Sale (S) | Common Stock | 32,263 | USD 7.17 | USD 231,326 | SEC filing ↗ |
| 2026-09-03 | EVNIN LUKE; Foley Todd; GADICKE ANSBERT; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM Asset Management Investors BV2014 LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2014 (B), L.P.; MPM BioVentures 2014 GP LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014, L.P. | Sale (S) | Common Stock | 32,263 | USD 7.17 | USD 231,326 | SEC filing ↗ |
| 2026-09-02 | WENTWORTH KORY JAMES | Tax withholding (F) | Common Stock | 1,733 | USD 7.14 | USD 12,374 | SEC filing ↗ |
| 2026-09-02 | Sethuraman Natarajan | Tax withholding (F) | Common Stock | 2,079 | USD 7.14 | USD 14,844 | SEC filing ↗ |
| 2026-09-02 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 GP LLC; MPM BioVentures 2018 LLC | Sale (S) | Common Stock | 25,131 | USD 7.19 | USD 180,692 | SEC filing ↗ |
| 2026-09-02 | EVNIN LUKE; Foley Todd; GADICKE ANSBERT; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM Asset Management Investors BV2014 LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2014 (B), L.P.; MPM BioVentures 2014 GP LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014, L.P. | Sale (S) | Common Stock | 25,131 | USD 7.19 | USD 180,692 | SEC filing ↗ |
| 2026-09-02 | Dowden Nathan J | Tax withholding (F) | Common Stock | 2,528 | USD 7.14 | USD 18,050 | SEC filing ↗ |
| 2026-09-02 | Doshi Dipal | Tax withholding (F) | Common Stock | 8,724 | USD 7.14 | USD 62,289 | SEC filing ↗ |
| 2026-09-01 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 GP LLC; MPM BioVentures 2018 LLC | Sale (S) | Common Stock | 29,088 | USD 7.06 | USD 205,361 | SEC filing ↗ |
| 2026-09-01 | EVNIN LUKE; Foley Todd; GADICKE ANSBERT; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM Asset Management Investors BV2014 LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2014 (B), L.P.; MPM BioVentures 2014 GP LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014, L.P. | Sale (S) | Common Stock | 29,088 | USD 7.06 | USD 205,361 | SEC filing ↗ |
| 2026-08-31 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 GP LLC; MPM BioVentures 2018 LLC | Sale (S) | Common Stock | 44,259 | USD 6.99 | USD 309,370 | SEC filing ↗ |
| 2026-08-31 | EVNIN LUKE; Foley Todd; GADICKE ANSBERT; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM Asset Management Investors BV2014 LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2014 (B), L.P.; MPM BioVentures 2014 GP LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014, L.P. | Sale (S) | Common Stock | 44,259 | USD 6.99 | USD 309,370 | SEC filing ↗ |
| 2026-08-28 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 GP LLC; MPM BioVentures 2018 LLC | Sale (S) | Common Stock | 3,733 | USD 7.01 | USD 26,168 | SEC filing ↗ |
| 2026-08-28 | EVNIN LUKE; Foley Todd; GADICKE ANSBERT; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM Asset Management Investors BV2014 LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2014 (B), L.P.; MPM BioVentures 2014 GP LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014, L.P. | Sale (S) | Common Stock | 3,733 | USD 7.01 | USD 26,168 | SEC filing ↗ |
| 2026-08-27 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 GP LLC; MPM BioVentures 2018 LLC | Sale (S) | Common Stock | 38,922 | USD 7.20 | USD 280,238 | SEC filing ↗ |
| 2026-08-27 | EVNIN LUKE; Foley Todd; GADICKE ANSBERT; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM Asset Management Investors BV2014 LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2014 (B), L.P.; MPM BioVentures 2014 GP LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014, L.P. | Sale (S) | Common Stock | 38,922 | USD 7.20 | USD 280,238 | SEC filing ↗ |
| 2026-08-26 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 GP LLC; MPM BioVentures 2018 LLC | Sale (S) | Common Stock | 14,569 | USD 7.06 | USD 102,857 | SEC filing ↗ |
| 2026-08-26 | EVNIN LUKE; Foley Todd; GADICKE ANSBERT; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM Asset Management Investors BV2014 LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2014 (B), L.P.; MPM BioVentures 2014 GP LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014, L.P. | Sale (S) | Common Stock | 14,569 | USD 7.06 | USD 102,857 | SEC filing ↗ |
| 2026-08-25 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 GP LLC; MPM BioVentures 2018 LLC | Sale (S) | Common Stock | 26,522 | USD 7.54 | USD 199,976 | SEC filing ↗ |
| 2026-08-25 | EVNIN LUKE; Foley Todd; GADICKE ANSBERT; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM Asset Management Investors BV2014 LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2014 (B), L.P.; MPM BioVentures 2014 GP LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014, L.P. | Sale (S) | Common Stock | 26,522 | USD 7.54 | USD 199,976 | SEC filing ↗ |
| 2026-08-24 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 GP LLC; MPM BioVentures 2018 LLC | Sale (S) | Common Stock | 21,623 | USD 7.34 | USD 158,713 | SEC filing ↗ |
| 2026-08-24 | EVNIN LUKE; Foley Todd; GADICKE ANSBERT; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM Asset Management Investors BV2014 LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2014 (B), L.P.; MPM BioVentures 2014 GP LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014, L.P. | Sale (S) | Common Stock | 21,623 | USD 7.34 | USD 158,713 | SEC filing ↗ |
| 2026-08-10 | PARMAR KUSH | Sale (S) | Common Stock | 92,444 | USD 7.00 | USD 647,108 | SEC filing ↗ |
| 2026-08-07 | PARMAR KUSH | Sale (S) | Common Stock | 52,317 | USD 6.85 | USD 358,371 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-18 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | TRDA |
| CIK | 0001689375 |
| Sector | Healthcare |
| Industry | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| Exchange | Nasdaq |
Data coverage
| Local Form 4 history | 438 transaction lines from 2021-11-02 to 2026-09-09 61 P purchase lines · 217 S sale lines · 160 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.